3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Terminated
2
Recruiting
2
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
5
Neoplasms
5
Neoplasm Metastasis
4
Advanced Solid Tumors
4
Leukemia, Myeloid, Acute
3
Triple Negative Breast Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Carcinoma, Renal Cell
2
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrent Squamous Cell Lung Carcinoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Fanconi Anemia, Complementation Group D1
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Childhood Solid Tumors
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Breast Adenocarcinoma
1
Advanced Solid Tumor
1
Interventions
Carboplatin
87
Paclitaxel
77
Bevacizumab
38
Topotecan
23
liposomal doxorubicin
22
Gemcitabine
22
Taxes
21
Cisplatin
17
Drug Therapy
14
Docetaxel
14
Cyclophosphamide
14
pembrolizumab
13
Immunoglobulin G
12
Disulfides
12
veliparib
8
rucaparib
8
mirvetuximab soravtansine
8
niraparib
7
Albumin-Bound Paclitaxel
7
sargramostim
6
Filgrastim
6
Erlotinib Hydrochloride
6
Doxorubicin
6
pazopanib
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Chemotherapy, Adjuvant
5
CP protocol
5
trebananib
4
temsirolimus
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Fallopian Tube Neoplasms
×
talazoparib
×
Clear all
NCT02316834
2022-02-24
POSITION
M.D. Anderson Cancer Center
Phase EARLY_PHASE1
Completed
4 enrolled